The Latest Breaking News from FDA

In 2024, the FDA will decide whether or not MDMA can be used to treat patients suffering from PTSD.

The myriad potential harms of these products are wide-ranging

The pharmaceutical industry holds immense promise due to the rapidly aging population, growing healthcare needs, breakthroughs in new drugs and therapies, and the rise in chronic diseases. Therefore, it could be wise to add fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Eton Pharmaceuticals (ETON), and Viatris (VTRS) to one’s portfolio.…

The Federal Trade Commission has challenged more than 100 patents drugmakers listed in the FDA’s “Orange Book"

The Supreme Court will soon decide the fate of access for mifepristone. The fallout of a ban would be tremendous

The House approved a bipartisan bill that would expand the child tax credit. As tensions between Zelenskyy and his military chief rise, the EU agrees to more than $50 billion in aid for Ukraine.

A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday.

Growing medical needs, surging demand for precision medicine, favorable regulatory climate, and rapid digital transformation would create promising growth opportunities for pharma companies. Hence, it could be wise to invest in top pharma stocks Johnson & Johnson (JNJ), Spero Therapeutics (SPRO), Ipsen (IPSEY), and Procaps Group (PROC) for solid gains.…

The breathing machine manufacturer has faced relentless criticism over its handling of the 2021 recall of millions